About The Author

Professor Hergenrother received his B.S. in chemistry from the University of Notre Dame in 1994. He went on to the University of Texas at Austin and obtained his Ph.D. in 1999; during this time Paul was the recipient of an American Chemical Society graduate student fellowship and the Roche Award for Excellence in Organic Chemistry. After an American Cancer Society post-doctoral fellowship at Harvard University, he joined the faculty at Illinois in 2001. His research interests are in the areas of synthetic organic chemistry, chemical biology, and biochemistry.

"The overarching goal of our research is to use organic compounds to identify novel cellular targets that can be exploited in the treatment of diseases including cancer and drug-resistant bacteria. The compounds we discover are identified through a variety of approaches, including natural product synthesis, synthesis of complex-and-diverse compounds, structure-based design, and high-throughput screening. In the process, novel methods for the synthesis of various chemical building blocks and for biological assays often need to be developed. In addition, we work closely with the local medical community and perform tests directly on patient samples."

Combating Resistance To Targeted Anticancer Therapies Via Caspase-3-Mediated MEK Degradation

Increasingly, anticancer drugs targeting mutant or fusion proteins found in a patient’s tumor are becoming the gold standard for modern-day cancer treatment. This personalized approach to oncology has led to dramatic results in the clinic, with potent tumor reduction being observed in a variety of disease traditionally considered recalcitrant to treatment. While these drugs often